Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.